We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE Trial

MedXY Editorial Team•Jul 13, 2026•Gastroenterology
clinical trialCrohn’s diseaseDose Intensificationustekinumab

Highlight

This prospective randomized trial investigated dose intensification with ustekinumab in Crohn’s disease patients experiencing secondary loss of response. Two regimens – intravenous reinduction plus either every 4-week or every 8-week subcutaneous maintenance dosing – were compared over 48 weeks. Steroid-free clinical remission rates were low and statistically similar between groups, with comparable safety profiles.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unveiling the TL1A-LTα1β2/IL-22 Axis: A New Therapeutic Target in Crohn’s Disease with Perianal Fistulising DiseaseThis study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis inSep 19, 2026Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE TrialThe phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensiveSep 9, 2026Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCTA pilot randomized trial comparing targeted temperature management at 35°C versus normothermia in intubated heatstroke patients showed no survival or neurological benefit from hypothermia but increased gastrointestinal injury and arrhythmiaSep 3, 2026Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.
Sep 1, 2026
Early Childhood Exposure to Crohn’s Disease-Affected Siblings: Implications for Gut Microbiome and Disease SusceptibilityChildhood exposure to siblings with Crohn’s disease significantly raises disease risk, linked to distinct gut microbiome changes that may drive disease onset through immune modulation.Aug 28, 2026
Individualized vs Standard Blood Pressure Control During Mechanical Thrombectomy for Acute Ischemic Stroke: Insights from the DETERMINE Randomized Clinical TrialA randomized clinical trial comparing individualized versus standard blood pressure control during mechanical thrombectomy for ischemic stroke showed no significant difference in 90-day functional outcomes or safety.Aug 24, 2026